AbbVie (WBO:ABBV) Long-Term Debt : €58,701 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AbbVie Long-Term Debt?

AbbVie's Long-Term Debt for the quarter that ended in Mar. 2024 was €58,701 Mil.

AbbVie's quarterly Long-Term Debt declined from Sep. 2023 (€52,126 Mil) to Dec. 2023 (€47,862 Mil) but then increased from Dec. 2023 (€47,862 Mil) to Mar. 2024 (€58,701 Mil).

AbbVie's annual Long-Term Debt declined from Dec. 2021 (€56,807 Mil) to Dec. 2022 (€55,823 Mil) and declined from Dec. 2022 (€55,823 Mil) to Dec. 2023 (€47,862 Mil).

AbbVie Long-Term Debt Historical Data

The historical data trend for AbbVie's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Long-Term Debt Chart

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

56,677.50

63,749.39

56,807.27

55,823.44

47,861.90

AbbVie Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															55,378.73	51,514.48	52,126.25	47,861.90	58,700.60

AbbVie (WBO:ABBV) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

AbbVie Long-Term Debt Related Terms

Thank you for viewing the detailed overview of AbbVie's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (WBO:ABBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV34:Brazil

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.